Novozymes A/S (OTCMKTS:NVZMY – Get Free Report)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $66.35 and traded as low as $63.5440. Novozymes A/S shares last traded at $64.42, with a volume of 36,641 shares trading hands.
Analyst Ratings Changes
Separately, Zacks Research lowered Novozymes A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Novozymes A/S presently has an average rating of “Buy”.
Check Out Our Latest Research Report on Novozymes A/S
Novozymes A/S Trading Down 1.3%
Novozymes A/S Cuts Dividend
The business also recently declared a dividend, which was paid on Thursday, September 11th. Investors of record on Wednesday, September 3rd were paid a $0.1856 dividend. The ex-dividend date of this dividend was Tuesday, September 2nd. This represents a yield of 88.0%. Novozymes A/S’s dividend payout ratio (DPR) is currently 21.89%.
Novozymes A/S Company Profile
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Further Reading
- Five stocks we like better than Novozymes A/S
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 11/10 – 11/14
- Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio
- Are These 3 Oversold Tech Giants Ready to Rebound?
- What is the S&P 500 and How It is Distinct from Other Indexes
- If You Wait for the Dip, Micron Technology Could Leave You Behind
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
